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Abstract
CLEC4F, a member of C-type lectin, was first purified from rat liver extract with high binding affinity to fucose, galactose
(Gal), N-acetylgalactosamine (GalNAc), and un-sialylated glucosphingolipids with GalNAc or Gal terminus. However, the
biological functions of CLEC4F have not been elucidated. To address this question, we examined the expression and
distribution of murine CLEC4F, determined its binding specificity by glycan array, and investigated its function using CLEC4F
knockout (Clec4f2/2) mice. We found that CLEC4F is a heavily glycosylated membrane protein co-expressed with F4/80 on
Kupffer cells. In contrast to F4/80, CLEC4F is detectable in fetal livers at embryonic day 11.5 (E11.5) but not in yolk sac,
suggesting the expression of CLEC4F is induced as cells migrate from yolk cells to the liver. Even though CLEC4F is not
detectable in tissues outside liver, both residential Kupffer cells and infiltrating mononuclear cells surrounding liver
abscesses are CLEC4F-positive upon Listeria monocytogenes (L. monocytogenes) infection. While CLEC4F has strong binding
to Gal and GalNAc, terminal fucosylation inhibits CLEC4F recognition to several glycans such as Fucosyl GM1, Globo H,
Bb3,4 and other fucosyl-glycans. Moreover, CLEC4F interacts with alpha-galactosylceramide (a-GalCer) in a calcium-
dependent manner and participates in the presentation of a-GalCer to natural killer T (NKT) cells. This suggests that CLEC4F
is a C-type lectin with diverse binding specificity expressed on residential Kupffer cells and infiltrating monocytes in the
liver, and may play an important role to modulate glycolipids presentation on Kupffer cells.
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Introduction
CLEC4F (also known as Kupffer cell receptor, KCR) was first
purified from rat liver extract by affinity chromatography on L-
fucosyl-bovine serum albumin (BSA)-Sepharose column and was
reported as a hepatic fucose-binding lectin. This suggested that rat
CLEC4F (rCLEC4F) serves as fucose receptor [1,2]. Further
studies showed that rCLEC4F has high binding affinity for Gal
and GalNAc [1,3], desialylated, complex N-link glycan [4] and
glycolipids, such as Gb4Cer (GalNAcb1-3Gala1-4Galb1-
4GlcblCer), Gb5Cer (GalNAca1-3GalNAcb1-3Gala1-4Galb1-
4GlcblCer) and LacCer (Galb1-4GlcblCer) but not ganglinoside
[5]. Based on the recognition patterns, rCLEC4F may have
functions paralleling to mammalian CLEC4H/asialoglycoprotein
receptor [4] and may also participate in the clearance of
circulating Gal- and fucose-terminated glycoproteins from blood
[4,6].
The rCLEC4F is a 550 amino acid type II transmembrane C-
type lectin [7] and the C-terminal domain of rCLEC4F is
homologous to the carbohydrates recognition domain (CRD) of
other mammalian C-type lectins, such as langerin, asialoglyco-
protein receptor and collectin. The extracellular domain of
rCLEC4F exists as a trimer stabilized by the neck region [4].
The expression of rCLEC4F was shown to be exclusively present
on resident liver macrophages [2], thus rCLEC4F is also named as
Kupffer cell receptor/KCR. Kupffer cells are heterogeneous and
are the largest population of tissue macrophages located in the
liver within the lumen of hepatic sinusoids [8,9,10]. F4/80 is the
pan marker for murine tissue macrophages [11,12,13]. In general,
murine Kupffer cells were identified by F4/80+ cells in the liver.
However, there is no suitable marker to distinguish Kupffer cells
from other tissue macrophages and the mononuclear phagocyte
system. Hence, studies on the ontogeny of Kupffer cells are still
controversial [9,13]. Recent studies show that the mRNA
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expression level of CLEC4F was enriched in carbon-labeled
Kupffer cells [14] and hepatic inflammation [15], but was
decreased or lost in Kupffer cells-depleted livers [16,17].
Nevertheless, the expression of CLEC4F in the mononuclear
phagocyte system and tissues are not confirmed yet. Therefore, we
would like to examine both the mRNA and protein level of
CLEC4F to clarify the distribution and specificity of CLEC4F.
CLEC4F belongs to the C-type lectin family, but its biological
functions are not well elucidated yet. It has been shown that
members of the C-type lectin family are involved in the delivery of
lipid antigens to antigen presenting cells. The lipoarabinomannan
has been shown to be internalized and delivered to late endosomal
and lysosomal compartments by the CLEC13D/CD206/macro-
phage mannose receptor [18], while the presentation of CD1a-
dependent lipid antigens is blocked by antibodies to CLEC4K/
CD207/langerin [19]. NKT cells are a unique lineage of T cells
that express NK lineage receptors and semi-invariant CD1d-
restriced ab TCRs [20,21] and can be activated by glycolipid a-
GalCer [22]. Upon stimulation, NKT cells produce large amounts
of IL-4, IFN-c and other cytokines, potentially enabling them to
act as powerful regulators of the immune system [23]. Mouse
NKT cells represent about 0.5% of the T cell population in blood,
peripheral lymph node, and spleen. Almost 30% of the T cells in
the liver have the NKT cell phenotype [24]. It has been shown
that Kupffer cells are the key antigen presentation cells for hepatic
NKT cells [25]. However, the role of Kupffer cells in glycolipid
presentation and NKT activation is still controversial. During
Borrelia burgdorferi infection, Kupffer cells form stable contacts with
NKT cells via CD1d, which lead NKT cells activation [26]. In
contrast, other studies have shown Kupffer cells were not required
in the development of a-GalCer-induced liver injury [27] or a-
GalCer-induced NKT cell hyporesponsiveness [28]. Therefore, we
are interested in understanding whether CLEC4F is involved in
presentation of a-GalCer.
In order to investigate these issues, anti-CLEC4F monoclonal
antibodies (mAbs) and Clec4f2/2 mice were generated to
determine the expression and distribution of CLEC4F-positive
(CLEC4F+) cells, and to understand the ontogeny of Kupffer cells.
Moreover, mice were challenged with L. monocytogenes to examine
the distribution of CLEC4F+ cells and investigate its function in
host defense. Here we reported that CLEC4F is expressed on
residential Kupffer cells and F4/80-positive cells infiltrating into
liver. Furthermore, CLEC4F is involved in the presentation of a-
GalCer to NKT cells, suggesting CLEC4F is not only a tissue
macrophage-specific marker, but may also play a role in glycolipid
presentation.
Materials and Methods
Animals
C57BL/6 mice were obtained from the National Laboratory
Animal Center, Taiwan. Clec4f2/2 mice were generated by
homologous recombination in ES cells (AB2.2, 129/SvEv strain)
(Figure S1 in File S1) and backcrossed onto C57BL/6 background
for more than eight generations. To destroy the clec4f gene, the
targeting vector was constructed to inset the enhanced green
fluorescent protein (EGFP) gene into the exon 4 of clec4f gene to
disrupt the expression of endogenous CLEC4F. Murine genomic
DNA of clec4f was obtained by screening lambda phage library
derived from mouse 129Sv/Ev strain. The 3.7 kb EcoRI DNA
fragment, which contains exon 1, exon 2, exon 3 and partial exon
4 of Clec4f gene, and the 2.3 kb EcoRI/HindIII DNA fragment,
which contains exon 5, were used for the left arm and right arm of
targeting vector, respectively. The Clec4f targeting vector, which
contains EGFP and neomycin selection cassette, was linearized
with KpnI and transfected into AB2.2 ES cells by electroporation.
Targeted ES cells were screened by Southern blot analysis using a
specific 39-flanking probe and then were injected into C57BL/6
blastocysts. Chimeric male mice were bred with C57BL/6 females.
Germ-line transmission was obtained from their agouti progeny.
All animal protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) in Taiwan. All mice were bred
and housed at the laboratory animal center, and the procedures
were approved by the Institutional Animal Care and usage
committee of National Yang-Ming University.
Cloning, Expression and Purification of Murine CLEC4F
The full-length of murine CLEC4F was cloned by reverse-
transcription polymerase chain reaction (RT-PCR) using BALB/c
liver cDNA as templates (forward primer: 59-AAGGAGGCG-
GAACTGAACA-39; reverse primer: 59-CTAGCC-
TACTCTGGCCGC-39) and subcloned into pFLAG-CMV2
vector (Kodak Co.). The expression of full length CLEC4F was
expressed by transfecting the pFLAG-CMV2-CLEC4F into 293T
cells and confirmed by Western blot using anti-FLAG M2 mAb
(Sigma-Aldrich). The extracellular domain of CLEC4F was cloned
by similar methods, except the forward primer was replaced with
59-CTAGCCTACTCTGGCCGC-39. The cDNA fragment of
CLEC4F ECD was subcloned into pcDNA/3hIgG1.Fc to
generate C-terminal hIgG1 Fc-tagged fusion proteins. The
recombinant Fc.CLEC4F fusion protein was overexpressed using
the FreeStyle 293 Expression System (Invitrogen) and the
recombinant Fc.CLEC4F fusion protein was purified by Protein
A columns (GE Healthcare) [29].
Generation and Screen of Anti-CLEC4F mAbs
BALB/c mice were immunized with purified recombinant
CLEC4F protein as antigen mixed with complete Freund’s
adjuvant (Sigma-Aldrich). The suitable mouse with highest titer
was selected for administration of the final boost. Total splenocytes
were fused with mouse myeloma NS-1 cells in the presence of 50%
(v/v) polyethylene glycol (PEG1450, Sigma-Aldrich). Fused cells
were cultured in HAT selection medium and the medium was
refreshed after one week. 2 weeks after fusion, culture supernatants
were screened by ELISA to identify the candidate clones for
further analysis by limiting dilution. Anti-CLEC4F mAbs were
selected by ELISA-based differential screening, and only those
recognizing recombinant CLEC4F were regarded as positive
clones.
RNA Isolation and Real-time Quantitative RT-PCR (qRT-
PCR)
Total RNA was extracted from cells or tissues by using Trizol
Reagent (Invitrogen). RNA (2 mg) was reverse transcribed in to
complementary DNA (cDNA) by using oligo(dT) primers and
Strata-ScriptTM RT-PCR kit (Stratagene). Quantitative RT-PCR
reactions were set up in duplicate with the Power SYBR Green
Master Mix (Roche) and analyzed with the Stratagene
Mx3000PTM Real-Time PCR System. Comparative CT method
was used to determine the relative quantification of target genes,
CLEC4F (forward primer: 59-CTTCGGGGAAGCAACAACTC-
39, reverse primer: 59- CAAGCAACTGCACCAGAGAAC-39)
and F4/80 (forward primer: 59-CAAGACTGACAACCAGACG-
39, reverse primer: 59-ACAGAAGCAGAGATTATGACC-39)
normalized to a reference gene GAPDH (forward primer: 59-
GCATCCACTGGTGCTGCC-39, reverse primer: 59- TCAT-
Kupffer Cell Receptor
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CATACTTGGCAGGTTTC-39). Nuclease-free water was used
as no-template-contained negative control.
Western Blot Analysis
Cell and tissue samples were homogenized in RIPA buffer
(50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 0.5%
Na-deoxycholate, and 0.1% SDS) with complete protease
inhibitor cocktail (Roach). A total protein of 20,100 mg was
fractionated by 10% SDS-PAGE before transfer to nitrocellulose
membrane, and subsequently probed with anti-CLEC4F mAbs
(clone 3E3F9, 2 mg/ml), anti-GAPDH (Chemicon, 1:1000), or
anti-FLAG M2 Ab (Sigma-Aldrich, 1:1000) followed by incuba-
tion with horse Radish peroxidase (HRP)-conjugated secondary
antibody. Membranes were developed with Western Chemilumi-
nescent HRP Substrate (ECL)(Millipore) and exposed to X-ray
film (FUJIFILM).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (5 mm) were
deparaffinized, dehydrated, and treated with antigen retrieval
buffer (0.01 M sodium citrate, pH 6.0). Sections were stained with
primary antibodies: anti-CLEC4F mAb (clone 3E3F9, 2 mg/ml)
and anti-F4/80 polyclonal Ab (M-300, 4 mg/ml, Santa Cruz)
followed by HISTOMOUSETM-MAX kit (Zymed) according to
the vendor’s instructions. Mouse IgG1 and rabbit Ig were used as
isotype controls, respectively.
Immunofluorescent Staining
Livers were perfused with PBS and fixed in 4% paraformalde-
hyde overnight and immersed in a serial concentration of sucrose
(10% R 20% R 30%). Cryosections (5 mm) of OCT-embedded
liver tissue were fixed in iced acetone for 5 min, then air-dried,
followed by soaking in PBS for 5 min and incubated 3 times, for
10 min each in sodium borohydride solution (1 mg/ml in PBS).
Sections were then stained with rabbit anti-F4/80 anti-sera (1:200)
and anti-CLEC4F (clone 3E3F9, 2 mg/ml), followed by FITC-
conjugated goat anti-rabbit IgG and Cy3-conjugated goat-anti-
mouse IgG. Nuclei were counterstained with Hoechst 33342.
Mouse IgG1 and rabbit Ig were used as isotype controls,
respectively. 0.3% Sudan Black in 70% EtOH were applied to
slides for 10 min and then rinsed with PBS to reduce autofluo-
rescence. After mounting, Specimens were analyzed using a
confocal microscope (LSM510META; Carl Zeiss) with a narrow
band pass filter. Confocal images were obtained using a 636 oil-
immersion lens.
Flow Cytometric Analysis
For cell surface staining, 16105 cells were preincubated with rat
anti-mouse CD16/32 mAb (clone 2.4G2, 1 mg/ml) and mIgG
(5 mg/ml) in 50 ml of FACS blocking buffer (5% (v/v) FCS, 0.1%
NaN3, 5 mM EDTA in PBS) at 4uC for 10 min to prevent
nonspecific binding through the Fc receptor. Cells were then
incubated with PE-conjugated anti-CLEC4F (clone 3E3F9, 2 mg/
ml) and Alexa Fluor 647-conjugated anti-F4/80 (AbD Serotec,
1:50) simultaneously at 4uC for 20 min. PE-conjugated mIgG1
and Alexa Fluor 647-conjugated rat IgG2b were used as isotype
controls, respectively. All samples were analyzed by FACSCalibur
(BD Biosciences) using FlowJo software.
Liposome Preparation and Kupffer Cell Depletion
Liposomes were prepared as described previously [30,31]. In
brief, 34.4 mg phosphatidylcholine and 3.2 mg cholesterol were
dissolved in 4 ml chloroform in a 50 ml round-bottom flask. The
thin phospholipid film was formed against the inner wall of the
flask under low vacuum rotation evaporation. The phospholipid
film was dispersed in 4 ml PBS or 0.6 M Cl2MBP by gentle
rotation at room temperature to generate the PBS-encapsulated
liposome and Cl2MBP-encapsulated liposome, respectively. The
milky white suspension was kept at RT for 2 h under nitrogen (N2)
gas for swelling. After sonication, liposomes were washed by PBS
twice and collected by centrifugation. The pellets were resus-
pended in 1.6 ml sterilized PBS and stocked in 4uC under N2 gas.
Kupffer cells were completely eliminated after 24 h with
intravenous injection of Cl2MBP-encapsulated liposome (100 ml
per mouse).
Pathogens
L. monocytogenes were prepared as described previously [32]. In
brief, L. monocytogenes were grown in tryptic soy broth (Difco
Laboratories) at 37uC in an orbital shaker overnight and stored at
280uC with glycerol in small aliquots. The CFU concentration of
the frozen infectious stocks were determined by plating a 10-fold
serial dilution onto tryptic soy agar plates and used for further
infection experiments.
Direct Binding and Completive Binding of CLEC4F with a-
GalCer and its Derivatives
a-GalCer was printed on the microarrays by the method
reported previously [33]. Fc.CLEC4F fusion protein was diluted in
the binding buffer (1% BSA, 150 mM NaCl, 2 mM CaCl2, 2 mM
MgCl2, 0.05% Tween 20 and 20 mM Tris-HCl, pH7.4) and then
directly applied to the sub-array of glass slides. Humidifying
incubation was performed under foil for 1 h at room temperature.
The slide was then washed using the following procedure: (1)
washed three times with incubation buffer, (2) three times with
distilled water, and (3) dried with a flow of argon gas. A solution of
Cy3-labeled anti-Fc antibody was incubated on the slide for 1 h.
The slide was again washed using the above procedure and the
fluorescence visualized at a resolution of 5 A˚ m with a 595 nm
laser using an ArrayWorx microarray reader (Applied Precision).
For the competitive binding assay, solutions of the competitors at
different concentration (5 mM to 0.1 mM) were prepared and 5 ml
aliquots incubated with protein (5 ml, 25 mg/mL). An aliquot of
this solution (8 mL) was loaded onto the slides and incubated for
1 h under a humidifying container at room temperature. The
following procedure is the same as the direct binding assay in
applying secondary antibody. To get the data, every inhibitor was
assayed under this system at least 3 times to present the binding
curves.
Glycan Microarray Fabrication
Microarrays were printed (BioDot, Cartesian Technologies)
onto NHS-coated glass slides by robotic pin (SMP3, TeleChem
International Inc.) deposition of ,0.7 nL amine-functionalized
glycans in printing buffer (300 mM phosphate buffer, pH 8.5,
0.005% Tween-20). Each microarray slide was spotted with
50 mM of glycan, with a total of 63 glycans in an array. Printed
slides were allowed to react and dry for one hour in the
atmosphere of 80% humidity followed by desiccation overnight.
These slides were then stored in a desiccator at room temperature
before use.
Analysis of Glycan-binding Profile
Fc.CLEC4F fusion protein (5 mg/ml) in binding buffer was
applied onto glycan array slides (printed with 63 glycans, Table S1
in File S1) and incubated for 1.5 h at room temperature. After a
Kupffer Cell Receptor
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sequential washing step with TBST, TBS, and distilled water, a
secondary 40-min-incubation was done by applying DyLight 549
conjugated-goat anti-human IgG (5 mg/ml in binding buffer) onto
the slides. Slides were scanned at 532 nm with ArrayWorx chip
reader (Applied Precision) after washing and blow-dry. The
median density of each spot was analyzed by ArrayVision (GE
Healthcare), and the density of each replicate set was then
calculated to give ‘‘Average Binding Intensity’’ and ‘‘SD (standard
deviation).’’
Isolation of Kupffer Cells and Hepatic Mononuclear Cells
(MNCs)
Kupffer cells were isolated by in situ collagenase perfusion
through the portal vein as described previously [34]. Briefly,
livers were perfused with 5 ml Hank’s balanced salt solution
(HBSS), followed by 12 ml digestion buffer (HBSS containing
0.5 mg/ml type VI collagenase (Sigma-Aldrich) and 10 mg/ml
DNase I (Roach)). The livers were removed, minced and
incubated in digestion buffer at 37uC for 20 min and then were
pressed through a 40 mm cell strainer. Parenchymal cells were
removed by low speed centrifugation at 50 g for 2 min. The
supernatant enriched in nonparenchymal cells was centrifuged
at 800 g for 30 min through a 25% (v/v) Percoll gradient at
room temperature with no brake. The pellets of the gradient
containing Kupffer cells and sinusoidal endothelial cells were
washed and seeded on culture plates and incubated at 37uC for
30 min to obtain the adherent Kupffer cells. Kuppfer cells were
rested for 1 day for flow cytometric analysis and further in vitro
NKT cell activation. Hepatic mononuclear cells (MNCs)
(including NKT cells) were isolated as described [35]. Briefly,
liver was perfused with 5 ml ice-cold HBSS slowly to eliminate
blood. Pale livers were removed, minced and incubated in
RPMI medium containing 0.05% collagenase and 10 mg/ml
DNase I at 37uC for 20 min and then were pressed through the
cell strainer. Suspended cells were fractionated by overlaying a
33% (v/v) Percoll solution followed by centrifugation at 800 g
for 30 min. After red blood cell lysing, the hepatic MNCs were
washed and cultured at 37uC with 5% CO2 for 1 hour; non-
adherent lymphocytes were obtained for further in vitro NKT
cells activation.
In vitro NKT Cells Activation
Kupffer cell (16105 cells/well) from wild-type or Clec4f2/2
littermates were loaded with indicated concentration of a-GalCer
for 3 h, then were co-cultured with hepatic MNCs (16105 cells/
well) to activate NKT cells for 72 h. The supernatant was collected
for detecting cytokine production. In the CD1d blocking
experiment, Kupffer cells were pretreated with CD1d blocking
antibody (clone 1B1, BD Biosciences) and were followed with a-
GalCer loading and NKT activation.
Cytokine Measurement by ELISA
Supernatants from a-GalCer treatment cells were collected and
stored at 220uC before being used. The levels of IL-4, and IFN-c
were determined using ELISA kits (R&D System).
Animal Model for a-GalCer-induced Hepatitis
12-wk-old wild-type or Clec4f2/2 mice were used for animal
study. a-GalCer was diluted in pyrogen-free saline to the indicated
doses through intravenous injection in a total volume of 200 ml/
mouse. Serum samples were collected at indicated time points for
ALT and cytokine assay.
Statistical Analysis
All data were shown as mean 6SD by using Prism software
(GraphPad). An unpaired Student’s t test was used to assess for
significance differences between the control groups and each
treated group. A p value of ,0.05 was regarded as significant. The
survival rate was determined by Kaplan-Meier analysis with a log-
rank test, and statistical significance was accepted at a p value of
,0.05.
Results
CLEC4F is a Glycosylated Protein Expressed Specifically in
Liver Kupffer Cells
The cDNA of murine CLEC4F (accession number: D88577)
contains a 1647 bp open reading frame (ORF) and a 194 bp 39
untranslation region (39-UTR). The translation of the ORF
predicts a polypeptide of 548 amino acids with a molecular weight
of 61 kDa, which shows 80% identity to rCLEC4F. The sequence
annotation of KUCR_MOUSE (P70194) revealed that the murine
CLEC4F is a type-II transmembrane protein with a short amino-
terminal domain (amino acid residues 1–42) in the N-terminus,
followed by a hydrophobic region (amino acid residues 43–69) as
transmembrane region; the third domain (amino acid residues 70–
437) contains six potential N-glycosylation sites at positions 86, 92,
115, 132, 209 and 255 residues, and the fourth domain is located
in the carboxyl terminus (amino acid residues 438–538) and
contains a typical C-type lectin domain, also known as CRD. The
CRD domain of CLEC4F displays the highest homology with
hepatic asialoglycoprotein receptors (ASGP-Rs) (46.2% identity),
followed by macrophage Gal/GalNAc specific lectins (MGLs)
(45.7% identity), langerin (43.8% identity) and DC-SIGN (42.5%
identity).
In contrast to F4/80, quantitative RT-PCR analysis revealed
that CLEC4F mRNA is only expressed in liver and freshly
isolated Kupffer cells, but not in all other tissues. In addition,
CLEC4F mRNA is not detectable in bone marrow cells, bone
marrow derived macrophages (BMDMs), peripheral blood cells
(PBLs) or murine macrophage cell lines RAW264.7 and J774
(Figure 1A). In order to confirm CLEC4F expression at the
protein level, recombinant CLEC4F was used to immunize
BALB/c mice to generate anti-CLEC4F mAbs. Western blot
analysis demonstrated the anti-CLEC4F mAb can recognize a
100 kDa protein in liver, which is 40 kDa more than predicted,
but not the rest of tissues (left panel, Figure 1B). Moreover,
CLEC4F is only detectable in fresh isolated Kupffer cells, but
not in bone marrow or peripheral blood leukocytes, which
contain monocytes (right panel, Figure 1B). In pFLAG-CMV-2/
CLEC4F-transfected 293T cells (human embryonic kidney cells),
anti-CLEC4F mAb detected polypeptides ranging from 100 kDa
to 61 kDa, and addition of tunicamycin reduced the molecular
weight of CLEC4F to 61 kDa (Figure 1C), indicating that
CLEC4F is a glycoprotein with 40 kDa N-linked glycan, while
the 70 kDa is the incompletely glycosylated form in CLEC4F-
transfected 293 T cells.
Co-expression of CLEC4F and F4/80 on Kupffer Cells
The localization of CLEC4F+ cells was determined by
immunohistochemistry. By using tissue array, we found that
CLEC4F is only expressed in liver sinusoid cells, but not in other
tissues (Figure S2 in File S1). For further confirmation of the
binding specificity of anti-CLEC4F mAb, liver sections from wild-
type (upper panel, Figure 2A) and Clec4f2/2 (lower panel,
Figure 2A) mice were used. The worm-like cells located in the
lumen of sinusoid were detectable by anti-CLEC4F mAb and anti-
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F4/80 Ab, respectively (upper panel, Figure 2A), while only anti-
F4/80 Ab, but not anti-CLEC4F mAb, could detect Kupffer cells
in Clec4f2/2 liver section (lower panel, Figure 2A). In Clec4f2/2
mice, the numbers and distribution of F4/80+ Kupffer cells are
Figure 1. The expression and distribution of CLEC4F. (A) Tissue distribution of CLEC4F transcripts were analyzed by qRT-PCR. F4/80 is the pan
macrophage marker. (B) The protein expression of CLEC4F was examined by Western blot. GAPDH was used as internal control. (C) CLEC4F is a
glycoprotein. The pFLAG-CMV-2/CLEC4F-transfected 293T cells were treated with tunicamycin at 1.5 mg/ml for indicated time periods to inhibit N-
linked glycosylation, and the molecular weight of CLEC4F was analyzed by Western blot. DMSO is the vehicle control. Mock indicates 293T cells
transfect with pFLAG-CMV-2. mLN, mesenteric lymph node; iLN, inguinal lymph node; KC, Kupffer cells; PBL, peripheral blood leukocytes; BM, bone
marrow cells; BMDM, bone marrow derived macrophages.
doi:10.1371/journal.pone.0065070.g001
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similar to wild-type mice, suggesting that CLEC4F is dispensable
for Kupffer cell development.
Moreover, F4/80 and CLEC4F co-expressed on Kupffer cells
and both signals overlapped perfectly as observed by confocal
microscope (Figure 2B). Flow cytometry analysis also demonstrat-
ed that the expression of CLEC4F is appearing on the surface of
Kupffer cells but not on peritoneal macrophages or other cell
populations in liver or macrophage cell lines (Figure 2C & Figure
S3 in File S1). These observations indicate that CLEC4F is only
expressed on F4/80+ Kupffer cells in liver.
Ontogeny of CLEC4F+ Cells
According to the mononuclear phagocyte system, bone marrow-
derived monocytes in the blood migrate and differentiate into
Kupffer cells in the liver [10,36]. However, macrophages have
been known to exist in the early stage of ontogeny long before the
initiation of bone marrow hematopoiesis and to develop first in the
yolk sac [37]. Since yolk sac-derived F4/80+ macrophages could
be detected in most tissues from embryonic day 10.5 (E10.5), we
wondered when and where CLEC4F+ cells can be detected during
mouse embryogenesis. To address this question, embryos, yolk
sacs and fetal livers were collected from various embryonic
development stages to detect the expression of CLEC4F. We
found that CLEC4F mRNA appeared in fetal liver from E11.5
and increased gradually, and reached adult levels at E18.5
(Figure 3A). Western blot analysis showed that the protein level
of CLEC4F appeared in fetal liver from E12.5 (Figure 3B), but not
in the yolk sac. Immunohistochemistry further showed that
CLEC4F+ cells were present in fetal liver from both E14.5 (before
the formation of bone marrow hematopoiesis) and E16.5
(Figure 3C). This observation suggests that CLEC4F is inducible
in macrophages when cells migrate from yolk sac into fetal liver,
and its expression is earlier than the formation of the mononuclear
phagocyte system.
Repopulation of CLEC4F+ and F4/80+ Cells after Cl2MBP-
liposome Depletion
Since CLEC4F expression is restricted to Kupffer cells, we
further compared the number of CLEC4F+ and F4/80+ cells in
liver under reconstitution or inflammatory stage. Firstly, we
examined the amount of CLEC4F+ and F4/80+ cells during
Kupffer cell repopulation after intravenous administration of
liposome-encapsulated dichloromethylene diphosphonate
(Cl2MBP) (Figure 4A & 4B). Kupffer cells could be depleted after
Cl2MBP-encapsulated liposome treatment and will repopulate
over time [16,17,31]. At day 1 post Cl2MBP-encapsulated
liposome injection, Kupffer cells were depleted completely and
no any F4/80+ or CLEC4F+ cells were detectable in liver
(Figure 4A). At day 3 post Cl2MBP-encapsulated liposome
injection, both CLEC4F+ and F4/80+ cells reappeared, with
similar number and distribution in the liver. The numbers of
CLEC4F+ and F4/80+ cells further increased and restored to
original levels at day 28. Figure 4B summarized the kinetic change
in the number of hepatic CLEC4F+ and F4/80+ cells after Kupffer
cell depletion by Cl2MBP-encapsulated liposome. This observa-
tion suggests that reconstituted Kupffer cells expressed both
CLEC4F and F4/80 simultaneously.
We also wondered whether the expression of CLEC4F was
induced when inflammatory monocytes enter the liver environ-
ment. Liver is the most important organ in clearance of blood-
borne bacteria and bacteria products, and during L. monocytogenes
infection, inflammatory myelomonocytic cells will be recruited
into the liver [38]. In order to address this question, mice were
challenged with L. monocytogenes to generate a liver inflammatory
stage to examine the population change of CLEC4F+ and F4/80+
cells during infection (Figure 4C&4D). We found that both the
numbers of CLEC4F+ and F4/80+ cells were increased dramat-
ically at day 1 post-infection, and increased at day 5 post-infection
in wild-type mice (Figure 4C). The distribution and the kinetic
change in the number of F4/80+ cells in L. monocytogenes infected
Clec4f2/2 mice were similar to those observed in wild-type mice
(Figure 4C&4D). This observation suggests that CLEC4F is not
only expressed in resident Kupffer cells, but also appeared in
infiltrating F4/80+ mononuclear cells. Further, the clearance of
blood-borne bacteria is generally attributed to Kupffer cells [39].
We also compared the susceptibility of wild-type and Clec4f2/2
mice to L. monocytogenes infection to test whether CLEC4f is
involved in bacterial infection. However, the survival rate of
Clec4f2/2 and wild-type littermates are similar (p = 0.772),
suggesting CLEC4F is not critical for host defense against L.
monocytogenes (Figure 4E).
CLEC4F has Diverse Binding Specificity and is Involved in
Glycolipid Presentation
To further explore the functions of CLEC4F, we fused the
extracellular domain of CLEC4F with hIgG1 Fc portion to
generate recombinant Fc.CLEC4F fusion protein, followed by
probing against glycan array to understand its binding specificity.
While recombinant Fc.CLEC4F fusion protein showed strong
binding to the glycans with terminal Gal/GalNAc such as Gb5,
Gb4, Gb3 and Gb2, it cannot bind to globo H (fucosyl Gb5). This
revealed that the a1,2-linked fucose appended at the terminus of
globo H was able to block the recognition of Fc.CLEC4F to
terminal Gal. This phenomenon was also observed in Fc.CLEC4F
binding to Lewis x and GM1, but not Lewis y epitope and fucosyl
GM1 (both Lewis y and fucosyl GM1 bearing a1,2-linked fucose
in the terminal). (Figure 5 & Table S1 in File S1). Thus,
fucosylation has profound inhibitory effect on CLEC4F binding to
glycans.
Based on its strong binding to Gal, we asked whether CLEC4F
is able to interact with a-GalCer (Figure 6A), which is a glycolipid
with Gal terminus and is a potent immunomodulator in the
activation of NKT cells [22,33,40]. We firstly asked whether
CLEC4F interacts with a-GalCer and plays a role in the
presentation to NKT cells. To address this question, recombinant
Fc.CLEC4F was incubated with surface-bound a-GalCer on
microarray. The binding affinity of Fc.CLEC4F with a-GalCer
was determined to be 100 nM (dissociation constant), indicating a
multivalent interaction of Fc.CLEC4F with a-GalCer (Figure 6B).
In a competitive binding experiment, a-GalCer and three
truncated derivatives (phytosphingosine, Gal, and ceramide) in
solution competed with immobilized a-GalCer for the binding
sites on the CLEC4F (Figure 6C). The binding strength was in an
order of a-GalCer.ceramide < Gal .phytoshpingosine. This
Figure 2. CLEC4F is co-expressed with F4/80 on liver Kupffer cells. (A) CLEC4F and F4/80 immunohistochemistry of parafilm-embedded liver
sections from wild-type and Clec4f2/2 mice. (B) Double immunofluorescence of CLEC4F and F4/80 in wild-type livers was performed. Nuclei were
counterstained with Hoechst 33342. Signals were determined by confocal microscope (magnification 10663). (C) Coexpression of CLEC4F and F4/
80 on Kupffer cells, but not peritoneal macrophages. Cells were double stained with Alexa Fluor 647-conjugated anti-F4/80 and PE-conjugated anti-
CLEC4F mAb. Alexa Fluor 647-conjugated rat IgG2b and PE-conjugated mIgG1 were used as isotype controls.
doi:10.1371/journal.pone.0065070.g002
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Figure 3. Expression of CLEC4F during embryogenesis. Yolk sac, embryo and fetal liver in various embryonic stages were collected for CLEC4F
detection by (A) qRT-PCR and (B) Western blot. Actin was used as internal control. (C) F4/80 and CLEC4F immunohistochemistry of fetal liver from
E14.5 and E17.5, respectively.
doi:10.1371/journal.pone.0065070.g003
Figure 4. CLEC4F+ cells were appeared in the liver environment under Kupffer cell depletion and inflammatory stage. (A) Kupffer cells
were depleted by Cl2MBP-encapsulated liposome by intravenous injection (100 ml/mouse) at day 0 and livers were harvest at day 1, 7, 14 and 28. F4/
80 and CLEC4F immunohistochemistry of liver sections were performed. (B) The numbers of F4/80+ or CLEC4F+ cells in livers were shown. For
generating inflammatory stage, wild-type and Clec4f2/2 littermates were infected with L. monocytogenes (16105 CFU/mouse) intravenously. (C) The
numbers of F4/80+ or CLEC4F+ cells in livers during L. monocytogenes infection. (D) Immunohistochemistry of L. monocytogenes infected livers of wild-
type and Clec4f2/2 mice at day 5 after infection. (E) Kaplan-Meier survival curves were shown for Clec4f2/2 or wild-type littermates with L.
monocytogenes infection. The p value was determined by Log-rank test.
doi:10.1371/journal.pone.0065070.g004
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observation indicates that both Gal and ceramide were involved in
Fc.CLEC4F and a-GalCer interactions. We further asked whether
CLEC4F is involved in a-GalCer presentation to hepatic NKT
cells. To address this question, Kupffer cells isolated from Clec4f2/
2 or wild-type littermates were incubated with a-GalCer, followed
by incubation with hepatic lymphocytes (including hepatic NKT
cells). We were surprised to find that the secretion of IFN-c is
downregulated in hepatic lymphocytes stimulated with a-GalCer-
loaded Clec4f2/2 Kupffer cells, while the production of IL-4 is
similar under the same conditions (Figure 6D). Interestingly,
blocking antibody against CD1d further suppressed the secretion
of IFN-c in a dose-dependent manner, and there is no difference
for IFN-c and IL-4 secretion between Clec4f2/2 and wild-type
Kupffer cells in the presence of high dose (15 mg/ml) anti-CD1d
mAb (Figure 6E). However, serum levels of ALT, IFN-c and IL-4
are similar between Clec4f2/2 and wild-type littermates (Figure 7),
suggesting dendritic cells and other antigen presenting cells in liver
can also present a-GalCer efficiently to NKT cells even in the
presence of CLEC4F.
Discussion
Kupffer cells are the largest and heterogeneous population of
resident macrophages in the liver [9]. The biological function of
Kupffer cells have been implicated in the pathogenesis of host
defense, bilirubin metabolism, ischemia-reperfusion injury, viral
hepatitis, steatohepatitis, alcoholic liver disease, intrahepatic
cholestasis, activation or rejection of the liver during liver
transplantation, and liver fibrosis, as well as non-alcoholic fatty
liver disease [41]. In this study, we demonstrated clearly that the
expression of CLECF4F is restricted on Kupffer cells, and
facilitates a-GalCer presentation to NKT cells. In addition,
CLEC4F displays diverse binding specificity to glycans. Thus,
CLEC4F is not only a Kupffer cell-specific marker, but may also
contribute to the presentation of other glycans and glycolipids to
activate NKT cells.
In contrast to F4/80, which is a constitutively expressed surface
marker for both peripheral and resident macrophages [12,13,42],
CLEC4F is inducible in the liver microenvironment. The first
evidence comes from the observation that CLEC4F is detectable
in fetal liver from E11.5, but not in yolk sac (Figure 3) during
embryogenesis. Yolk sac is the first organ where the macrophages
develop. It has been demonstrated that macrophages occur in the
yolk sac of animal and human embryos. The F4/80+ primitive
macrophages appear in murine yolk sac at E9, and then
differentiate into fetal macrophages [36,37,42,43,44]. Fetal liver
begins to form its fundamental structure at E10, and primitive
macrophages are detected in the hepatic sinusoid [36]. Our
findings suggest that the expression of CLEC4F appeared when
primitive macrophages migrated into fetal liver. The second
evidence comes from the observation that both the number of F4/
80+ and CLEC4F+ cells in the liver were increased and similar
during L. monocytogenes infection. (Figure 4D). This suggests the
Figure 5. Glycan binding profile of Fc.CLEC4F. Fc.CLEC4F (5 mg/ml) in binding buffer was applied onto glycan array slides. The
‘‘Average Binding Intensity’’ and ‘‘Standard Deviation (SD)’’ among eight glycan replicates were analyzed by ArrayVision software (GE Healthcare).
doi:10.1371/journal.pone.0065070.g005
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Figure 6. CLEC4F is involved in the presentation of a-GalCer to NKT cells. (A) The schematic structure of a-GalCer. (B) The binding curves
were obtained from the function of Fc.CLEC4F concentration and fluorescence intensity determined from array images. (C) Competition experiment
between solution and surface for Fc.CLEC4F binding to a-GalCer and three derivatives. At different concentration of the competitors, binding curves
were obtained from the bound Fc.CLEC4F concentration and fluorescence. (D) Secretion of IFN-c and IL-4 of NKT cells after incubation of a-GalCer
presented by Kupffer cells isolated from wild-type and Clec4f2/2 mice. Kupffer cells (16105 cells) isolated form wild-type and Clec4f2/2 littermates
were treated with serial concentration of a-GalCer (10, 30, 100, 300 and 1000 ng/ml) then co-cultured with NKT cells (16105 cells). The supernatant
were collected at 72 h post-stimulation and detected the IL-4 and IFN-c production by ELISA. (E) Effect of CD1d-blocking antibody in the a-GalCer
presentation by wild-type and Clec4f2/2 Kupffer cells. Kupffer cells were pretreated with CD1d blocking antibody. Three hours later, a-GalCer
(300 ng/ml) was added and co-cultured with NKT cells. The supernatant were collected at 72 h post-stimulation and detected the IL-4 and IFN-c
production by ELISA.
doi:10.1371/journal.pone.0065070.g006
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infiltrating F4/80+ cells become CLEC4F+ upon entry to the liver.
Finally, we found the expression of CLEC4F is lost when Kupffer
cells were cultured in vitro for 7 days (Figure S4 in File S1). In
addition, CLEC4F is not expressed on the murine Kupffer cell
line, KC13-2 [8] (Figure S3 in File S1), suggesting Kupffer cells
may fail to maintain CLEC4F expression under culture condition.
It would be interesting to understand what kinds of signals or
molecules are necessary to regulate CLEC4F expression in the
liver microenvironment in the future.
Several C-type lectin receptors, including Dectin-1, Dectin-2,
DC-SIGN, and Mincle have been shown to recognize cell wall
components of Candida albicans (C. albicans) [46,49,50]. We also
found that CLEC4F is able to interact with polysaccharides
isolated from C. albicans, but the survival rates of Clec4f2/2 mice
is similar to wild-type littermates after intravenous injection of C.
albicans (Figure S5A in File S1), even thought Clec4f2/2 Kupffer
cells were shown to be unresponsive to C. albicans compare to wild-
type Kupffer cells in vitro (Figure S5B in File S1). Furthermore,
there is no difference in histopathological change between
Clec4f2/2 and wild-type littermates (Figure S5C in File S1),
suggesting CLEC4F is dispensable in host defense against candida
invasion. Further study is necessary to reveal the functions of
CLEC4F in Kupffer cells-mediated immunomodulation in the
future.
Supporting Information
File S1 Figure S1, S2, S3, S4, S5 and Table S1. Figure S1
in File S1. Generation of Clec4f knockout mice. (A) Clec4f
targeting strategy. Genomic structure of the wild-type and targeted
alleles of Clec4f gene was destroyed by inserting the EGFP gene
into the exon 4 of Clec4f gene. (B) Southern blot hybridization of
genomic DNA from wild-type (+/+), heterozygous (+/2) and
homozygous (2/2) offspring by using 39-flanking probe. (C)
Western blot analysis of CLEC4F protein expression from liver
extracts. B: BamHI; E: EcoRI; EV: EcoRV; H: HindIII. Figure S2
in File S1. Characterization of CLEC4F expression by murine
tissue array screening. Immunohistochemistry of CLEC4F (B, D,
F, H, J, L, N, P, R) in mouse tissues, including liver (A, B), BM (C,
D), thymus (E,F), spleen (G, H), LN (I, J), brain (K, L), lung (M, N),
kidney (O, P) and gut (G, R) and mIgG1 was used as isotype
control (A, C, E, G, I, K, M, O, Q). Sections were counterstained
with hematoxylin. BM, bone marrow; LN, lymph node; M,
medulla; C, cortex; W, while pulp; R, red pulp; F, follicle. Scale
bar: 100 mm. Figure S3 in File S1. CLEC4F expression screening.
(A) CLEC4F-transfected 293T cells, (B) macrophage cell lines,
RAW264.7 and J774, and Kupffer cell line, KC13-2, and (C)
hepatic cell populations were used for CLEC4F staining. Cells
were stained with lineage markers: F4/80, NK1.1, B220 or TCR,
and double or triple stained with CLEC4F. Mouse IgG1 was used
as isotype control. Signals were determined by FACS Calibur for
Figure 7. Clec4f2/2 mice showed a similar response of a-GalCer induced activation to wild-type mice in vivo. Both wild-type and
Clec4f2/2 littermates were treated with a-GalCer (1 mg/mouse) intravenously. Serum levels of (A) ALT and (B) cytokines, including IL-4 and IFN-c
were analyzed for samples taken at indicated time points after a-GalCer challenge. Data are representative of three independent experiments with
similar results. (3 mice in each group).
doi:10.1371/journal.pone.0065070.g007
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flow cytometric analysis. Figure S4 in File S1. The expression of
CLEC4F is decreased under culture condition. Kupffer cells
isolated from C57BL/6 mice were cultured in RPMI 1640
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
at 37uC in 5% CO2. The expression of CLEC4F was detected by
Western blot in indicated culture time periods. Figure S5 in File
S1. CLEC4F is dispensable for C. albicans infection in vivo. (A)
The survival rate of wild-type and Clec4f2/2 littermates after C.
albicans infection. The p value was determined by using Kaplan-
Meier survival analysis and compared by Log-rank test. (B)
Kupffer cells (16105 cells) isolated from wild-type and Clec4f2/2
littermates were stimulated with heat-killed conidia (HK C), heat-
killed hyphae (HK H) and live conidida (L C) in 16106 CFU/ml.
The supernatant were collected at 24 h post-stimulation and
detected the level of IL-6 and TNF-a by ELISA. *: p,0.05; **:
p,0.01; ***: p,0.005. ‘‘n.d.’’ indicates non-detectable. (C) The
liver and kidney sections from C. albicans infected mice were
analyzed by H&E staining. Representative histopathological
sections of liver and kidney from mice infected with 16106
CFU of C. albicans. Table S1 in File S1. Glycan binding profile of
Fc.CLEC4F. Gal: galactose, GalNAc: N-acetylgalactosamine, Glc:
glucose, GlcNAc: N-acetylglucosamine, Man: mannose, Fuc:
fucose, Neu5Ac: N-acetylneuraminic acid, Neu5Gc: N-glycolyl-
neuraminic acid.
(PDF)
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